IRADIMED vs Pulse Biosciences
IRADIMED reported revenue of $84 million in fiscal 2025, 279.3 times Pulse Biosciences' $0 million in fiscal 2025. IRADIMED had an operating margin of 31.2%, against -21982.6% at Pulse Biosciences. Free cash flow was $17 million at IRADIMED and −$54 million at Pulse Biosciences.
Side by side
| IRADIMED | Pulse Biosciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $84M | $0M |
| Revenue growth | 14.4% | — |
| Revenue growth a year, last 5 years | 21.5% | — |
| Gross margin | 76.8% | −54.0% |
| Operating margin | 31.2% | −21,982.6% |
| Net margin | 26.8% | −20,794.6% |
| Free cash flow | $17M | −$54M |
| Free cash flow margin | 20.5% | −15,553.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $15M | $0M |
| Change in diluted share count | 0.6% | 15.4% |
| Last close | $85.35 | $50.44 |
| P/E at the last close | 45.6× | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | 3 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
IRADIMEDPulse Biosciences
Operating margin
Percent of revenue
IRADIMEDPulse Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
IRADIMEDPulse Biosciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the IRADIMED and Pulse Biosciences pages.